Cargando…
Soluble fms‐like tyrosine kinase‐1 to placental growth factor ratio: ruling out pre‐eclampsia for up to 4 weeks and value of retesting
OBJECTIVES: The soluble fms‐like tyrosine kinase‐1 (sFlt‐1) to placental growth factor (PlGF) ratio is generally elevated some time before and at the clinical onset of pre‐eclampsia. The PROGNOSIS study validated a sFlt‐1/PlGF ratio cut‐off of ≤ 38 to rule out the onset of pre‐eclampsia within 1 wee...
Autores principales: | Zeisler, H., Llurba, E., Chantraine, F. J., Vatish, M., Staff, A. C., Sennström, M., Olovsson, M., Brennecke, S. P., Stepan, H., Allegranza, D., Schoedl, M., Grill, S., Hund, M., Verlohren, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590225/ https://www.ncbi.nlm.nih.gov/pubmed/30014562 http://dx.doi.org/10.1002/uog.19178 |
Ejemplares similares
-
Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice
por: Stepan, H, et al.
Publicado: (2015) -
sFlt‐1/PlGF ratio test for pre‐eclampsia: an economic assessment for the UK
por: Vatish, M., et al.
Publicado: (2016) -
Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol
por: Hund, Martin, et al.
Publicado: (2014) -
Angiogenic factors: potential to change clinical practice in pre‐eclampsia?
por: Cerdeira, AS, et al.
Publicado: (2017) -
Associations Between Soluble fms‐Like Tyrosine Kinase‐1 and Placental Growth Factor and Disease Severity Among Women With Preterm Eclampsia and Preeclampsia
por: Hastie, Roxanne, et al.
Publicado: (2022)